Melane Sampson, Author at BioTuesdays

Developments

USPTO grants Clearmind patent for binge behavior regulators

Clearmind Medicine (NASDAQ: CMND) has been granted a U.S. patent titled “BINGE BEHAVIOR REGULATORS”, by the United States Patent and Trademark Office (USPTO). The patent, which refers to Clearmind’s molecule MEAI (5...

June 19, 2026

Developments

Seegnal launches first U.S. pilot program

Seegnal (TSXV: SEGN) has announced that it has successfully initiated its first pilot program in the U.S., following the letter of intent, announced on May 19, 2026. The company, dedicated to reducing medication-related...

June 19, 2026

Developments

AIM reports final patient dosed in Phase 2 study of Ampligen + Imfinzi in MPC

AIM Immunotech (NYSE American: AIM) has announced that the final patient has been dosed in the Phase 2 DURIPANC trial of Ampligen (rintatolimod) plus AstraZeneca’s (NYSE: AZN; LSE: AZN; STO: AZN) Imfinzi...

June 18, 2026

Developments

FDA grants GRI ODD for GRI-0621 in IPF

GRI Bio (NASDAQ: GRI) has announced that the FDA has granted Orphan Drug Designation (ODD) to GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, irreversible and ultimately fatal lung...

June 18, 2026

Developments

Cadrenal plans RPDD request for tecarfarin in KD

Cadrenal Therapeutics (NASDAQ: CVKD) announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin as a treatment for pediatric patients with Kawasaki disease (KD) who develop...

June 18, 2026

Developments

Verastem reports positive trial results for avutometinib combination in PDAC

Verastem Oncology (NASDAQ: VSTM) has announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a recommended Phase 2 dose cohort of 29 patients evaluating avutometinib plus defactinib in...

June 17, 2026

Developments

Matricelf advances toward first-in-human trial of spinal cord injury treatment

Matricelf (TASE: MTLF) announced the successful completion of its comprehensive GLP safety study for its engineered neural tissue implant, achieving all predefined study endpoints with no abnormal findings. According to...

June 17, 2026

Developments

Microbot signs agreement with Lovell expanding access to veteran and military populations

Microbot Medical (NASDAQ: MBOT) has entered into an agreement with closely held Lovell Government Services to serve federal healthcare systems, establishing Lovell as Microbot’s Service-Disabled Veteran-Owned Small...

June 16, 2026

Developments

Entera reports robust data for pipeline programs in HypoPT and obesity

Entera Bio (NASDAQ: ENTX) has reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its pipeline programs—EB612 in hypoparathyroidism (HypoPT) and EB618 in obesity and metabolic...

June 16, 2026

Feature

OS Therapies aims to activate the immune system to combat aggressive cancers in human and canine patients

OS Therapies (NYSE American: OSTX) is addressing the urgent need for innovative therapies to kill aggressive cancers that express HER2, including osteosarcoma—a rare and often fatal bone cancer—as well as other solid...

June 16, 2026

Author - Melane Sampson

USPTO grants Clearmind patent for binge behavior regulators

Seegnal launches first U.S. pilot program

AIM reports final patient dosed in Phase 2 study of Ampligen + Imfinzi in MPC

FDA grants GRI ODD for GRI-0621 in IPF

Cadrenal plans RPDD request for tecarfarin in KD

Verastem reports positive trial results for avutometinib combination in PDAC

Matricelf advances toward first-in-human trial of spinal cord injury treatment

Microbot signs agreement with Lovell expanding access to veteran and military populations

Entera reports robust data for pipeline programs in HypoPT and obesity

OS Therapies aims to activate the immune system to combat aggressive cancers in human and canine patients

Subscribe